List view / Grid view
28 October 2014 | By Eli Lilly &Company
Eli Lilly and Company LLY, -2.58% issued the following statement in response to a judge's ruling that the punitive damages awarded in the case of Terrence Allen, et al. v. Takeda Pharmaceuticals North America, Inc., et al, No. 6:12-cv-00064 be reduced...
28 October 2014 | By Boehringer Ingelheim
Global top 20 pharma company streamlines R&D IT with cross-domain platform...
28 October 2014 | By Bristol-Myers Squibb Company
Bristol-Myers Squibb Company and F-star Alpha Ltd. announced that the companies, together with the F-star Alpha Ltd. shareholders, have entered into an agreement that provides Bristol-Myers Squibb the exclusive option to acquire F-star Alpha Ltd, and gain worldwide rights to its lead asset FS102...
28 October 2014 | By Distributed by APO (African Press Organization) on behalf of SkyVision Global Networks Ltd
The fund will be used to cover expenses and the needs of Ebola patients and affected families...
28 October 2014 | By Moberg Pharma
Moberg Pharma AB announced that the first patient has been included in a randomized controlled phase ll study with BUPI, a novel topical formulation for the treatment of oral pain...
27 October 2014 | By Imaxio
Imaxio announces that it has been awarded funding of EUR 600,000 (USD 772,000) by the French National Research Agency (Agence Nationale de la Recherche, ANR) for the OPTIVAC project 'leveraging On t-cell immune resPonse To Improve influenza VACcines'...
27 October 2014 | By Roche
Roche announced that Esbriet® (pirfenidone) has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for an update to its European prescribing information, strengthening the efficacy claims and supporting the well-established safety profile based on the additional data from the phase III ASCEND trial...
27 October 2014 | By Genticel
Genticel announces its net cash position and its highlights from the third quarter of 2014...
27 October 2014 | By AB Consulting
The Chief Executive of Valeant, the Canadian based speciality drugmaker recently commented that ‘the pharmaceutical industry is stuck in the 1980’s with big bureaucratic R&D functions that produce little value’...
27 October 2014 | By The Institute of Cancer Research
The European Medicines Agency has approved olaparib for women with ovarian cancer who have a BRCA mutation - the first time a cancer drug has been approved targeted at an inherited genetic fault...
27 October 2014 | By Clinuvel Pharmaceuticals Limited
The first new pharmaceutical drug invented and developed for an untreated disorder by any Australian company has received regulatory approval from the European Medicines Agency (EMA). SCENESSE® (afamelanotide 16mg) treats the debilitating genetic disorder porphyria (EPP), or absolute intolerance to sunlight...
24 October 2014 | By Probiodrug
Probiodrug AG announces the successful completion of its Initial Public Offering, which was launched on 10 October 2014 (the “IPO” or the “Offering”)...
24 October 2014 | By electroCore
Preliminary results of an open-label trial carried in the journal of Headache and Pain reported that a single treatment with electroCore’s hand held non-invasive vagus nerve stimulation (nVNS) device gammaCore, completely resolved 44.8% of migraines within 30 minutes...
24 October 2014 | By European Medicines Agency
Rapid scientific advice to speed up development...
24 October 2014 | By GlaxoSmithKline
GSK announces Q3 core EPS of 27.9p +5% CER excluding divestments and dividend of 19 pence per share...
